Posts Tagged ‘Bell’
Perrigo Co. has built competitive advantages and diversified its revenue sources to help sustain future growth, according to a Barrington Research analyst who upgraded the stock and issued a glowing review of prospects for the company, which makes store-brand over-the-counter drugs and infant formulas.
Incoming search terms:
Related Posts:
UnitedHealth’s plan to buy a majority stake in a Brazilian health benefits and care provider makes sense for the U.S. health insurer, says a Goldman Sachs analyst, but the deal doesn’t resolve uncertainty about the health care overhaul that is keeping investors away from the stock.
Related Posts:
Shares of Sucampo Pharmaceuticals continued climbing Wednesday morning, a day after the drug developer said regulators will conduct a faster review of its drug Amitiza as a possible treatment for constipation caused by opioid pain drugs.
Related Posts:
Shares of dermatology products maker Medicis Pharmaceutical Corp. jumped 38 percent before the market open on Tuesday after it agreed to an approximately $ 2.6 billion offer from Valeant Pharmaceuticals International Inc.
Related Posts:
WellPoint Inc.’s second-quarter performance, which sent shares plummeting Wednesday, fuels some doubt about whether the health insurer can increase its enrollment without an acquisition and execute its business cleanly, according to a BMO Capital analyst.
Related Posts:
The settlement that Visa Inc. and MasterCard Inc. reached over a long-running lawsuit on the credit card fees they collect from retailers should finally alleviate investor concerns about the case’s impact, analysts said Monday.
Related Posts:
A Jefferies analyst downgraded WellPoint Inc.’s stock, a day after the health insurer posted fourth-quarter results that missed Wall Street expectations.
Incoming search terms:
Related Posts:
Shares of Vivus Inc. tumbled 16 percent Thursday in premarket trading a day after the drug developer released data linking an ingredient in a weight loss treatment it is developing to an increased risk of birth defects.
Incoming search terms:
Related Posts:
Competition to sell generic forms of Lipitor grew a little tighter Wednesday after Ranbaxy Laboratories Ltd. received regulatory approval to sell its version of Pfizer’s blockbuster cholesterol fighter.
Related Posts:
Shares of Endo Pharmaceuticals Holdings Inc. climbed more than 6 percent Thursday in pre-market trading, a day after the drug company said it received U.S. approval to market Fortesta gel to treat low testosterone in men.
All News, Video and Posts related to SECTOR: Health Care